Sanofi launches Toujeo DoubleStar in the UK

In the face of declining sales and price press in the insulin sector, the UK subsidiary of French drug major Sanofi (Euronext: SAN) today announced the launch of Toujeo (insulin glargine 300 units/mL) DoubleStar, a new long-acting insulin glargine injection pen recommended for adults with type 1 or type 2 diabetes mellitus, who require at least 20 units of basal insulin per day.

Delivering 2-160 units in a single injection, DoubleStar has the highest unit capacity of any basal insulin pen on the market.For patients requiring more than 20 units of insulin, DoubleStar will last longer compared to any other basal insulin pen.

Dr Mohamed Elnaggar,Associate Specialist of Diabetes and Endocrinology, University Hospitals of Morecambe Bay,said:“Diabetes is a chronic disease which currently affects 3.8 million people in the UK and is rising each year. It has a huge impact on the person’s day-to-day life, so treatment convenience is extremely important and must not be underestimated, as it can be crucial for helping patients to manage their condition.”